Investment Focus: We are raising a Seed round to finalize our FDA 510(k) pre-submission package, initiate a small-scale pilot study with a major US hospital system, and prepare for a scalable B2B commercial launch.

The Problem: Current remote cardiac monitoring solutions are bulky, expensive, and often suffer from high false-positive rates, leading to alarm fatigue and poor patient compliance.

The VitaSense Solution: Our device is a discreet, comfortable wearable that uses a novel algorithm trained on $10,000+$ hours of data to achieve 99.5% accuracy in arrhythmia detection, reducing hospital readmissions by a projected 30% in pilot data.

Funding Goal: We are seeking to raise $2.0 Million USD to cover the next 15-18 months of operational runway.

Use of Proceeds: Funds will be allocated primarily to:

1. Regulatory Acceleration: Finalizing bench testing and contracting specialized regulatory consultants for the FDA submission.
2. Clinical Validation: Executing a 50-patient pilot study to generate initial clinical proof-of-concept data.
3. Talent Acquisition: Hiring a dedicated Head of Regulatory Affairs and key software engineering personnel.

Market Traction: We have secured three Letters of Intent (LOIs) from major hospital networks for post-pilot adoption and have a robust patent portfolio securing our core intellectual property.

Investor Profile: We seek Angel groups or Seed-stage VCs with deep expertise in MedTech regulatory pathways and a strong network within hospital administration and payer systems. We offer a chance to invest in a low-dilution, high-impact device poised for rapid market penetration.